http://seekingalpha.com/article/2098...pt?part=single

Lastly, in August of 2013, we engaged Duke University in a clinical research master agreement, built around conducting the Phase I clinical trial of experimental use of neural stem cells in the treatment of Parkinson’s. Professor Mark Stacy, MD, Vice Dean of Clinical Research, Neurology at The Duke University School of Medicine, and an extremely well respected neurologist will be the study’s principal investigator.

Most recently in February 2014, the company held the pre IND meeting with the FDA, and subsequently announced that it will be working to complete the FDA required pharmacology and safety studies by the end of 2014 and file the IND shortly thereafter. In 2014, we will also be working towards bringing forward additional indications for these human neural stem cells.